GlobeNewswire by notified

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress

Share

Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care

Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients.

Galapagos is also hosting a hybrid symposium: Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through the jargon” will feature insights and answers to audience questions on putting patients at the heart of their RA care. Topics will be based on the new era in RA care, with the availability of JAK inhibitors along with a growing body of evidence providing a better understanding of the impact of pain and fatigue, as well as physical symptoms.

A number of abstracts will present trial data analyses on filgotinib, a once-daily oral preferential JAK-1 inhibitor, for the treatment of moderate to severe active RA. These include long-term efficacy and safety data, new analyses on the safety and efficacy of filgotinib in RA patients over the age of 75, and the effect of filgotinib on BMI and body weight. Additionally, Galapagos will present preclinical data on selective SIK3 (salt-inducible kinase) inhibition as a novel mode of action for the treatment of RA.

“The presentations capture our broad range of research and commitment to the RA community, demonstrating the importance of patient and clinical insights and highlighting our position as a science-driven company focusing on patient unmet needs,” said Walid Abi-Saab, MD, Chief Medical Officer at Galapagos. “We know that people living with RA continue to face daily challenges and we learn from their real experiences to inform our medicine development.”

Title Authors Time and Date
Safety of filgotinib in patients with rheumatoid arthritis: Analysis of lymphocytes in the long-term extension FINCH 4 study Jacques Eric Gottenberg, Gerd Burmester, Katrien Van Beneden, Chris Watson, Ineke Seghers, Vijay Rajendran, Lorenzo Dagna, Maya H Buch On-site & virtual display
Poster Number: POS0513
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)

Effect of filgotinib (FIL) on body weight (BW) and body mass index (BMI) and effect of baseline BMI on the efficacy and safety of FIL in rheumatoid arthritis (RA) Alejandro Balsa, Siegfried Wassenberg, Anne Tournadre, Hans-Dieter Orzechowski, Katrien Van Beneden, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, Patrick Verschueren On-site & virtual display
Poster Number: POS0518
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)
Efficacy and safety of filgotinib in patients aged ≥75 years: a post hoc subgroup analysis of the FINCH 4 long-term extension (LTE) study Daniel Aletaha, René Westhovens, Bernard G Combe, Jacques-Eric Gottenberg, Maya H Buch, Roberto Caporali, Jose A Gómez-Puerta, Paul van Hoek, Vijay Rajendran, Pieter-Jan Stiers, Thijs Hendrikx, Gerd R Burmester, Yoshiya Tanaka On-site & virtual display
Poster Number: POS0676
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)
The use of exposure-adjusted event rates versus exposure-adjusted incidence rates in adverse event reporting: insights from filgotinib integrated safety data in rheumatoid arthritis Patrick Durez, Eugen Feist, Ricardo Blanco, Vijay Rajendran, Nadia Verbruggen, Katrien Van Beneden, James Galloway On-site & virtual display
Poster Number: POS0663
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)
Physicians’ reasons for prescribing Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA), and associated alignment between physicians and patients in a real-world clinical setting Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero Yuste, Jasper Broen, Martin Welcker, Elizabeth Holdsworth, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke Alten On-site & virtual display
Poster Number: POS0680
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)

Clinical outcomes up to Week 48 of ongoing filgotinib (FIL) rheumatoid arthritis (RA) long-term extension (LTE) trial of biologic disease-modifying antirheumatic drug (bDMARD) inadequate responders (IR) initially on FIL or placebo in a Phase 3 parent study (PS) Maya H. Buch, Tsutomu Takeuchi, Vijay Rajendran, JE Gottenberg, Alena Pechonkina, YingMeei Tan, Qi Gong, Katrien Van Beneden, Roberto Caporali Abstract publication
Abstract number: AB0394

Integrated safety analysis update for filgotinib (FIL) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) receiving treatment over a median of 2.2 years (y) Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan J Kivitz, Mark C Genovese, Alena Pechonkina, Franziska Matzkies, Beatrix Bartok, Kun Chen, Deyuan Jiang, Iyabode Tiamiyu, Robin Besuyen, Sander Strengholt, Gerd R Burmester, Jacques-Eric GottenbergPoster tour presentation, on-site & virtual display
Poster Number: POS0235
Date: 3 June 2022, 12:10:00-12:18:00 CEST (poster tour)
Session: “Rheumatoid arthritis: JAKi and beyond”
Clinical outcomes of methotrexate (MTX)-naïve rheumatoid arthritis (RA) patients (pts) on filgotinib (FIL) long-term extension (LTE) trial initially on FIL or MTX during the Phase 3 parent study (PS) Daniel Aletaha, Rene Westhovens, Tatsuya Atsumi, YingMeei Tan, Alena Pechonkina, Qi Gong, Vijay Rajendran, Sander Strengholt, Gerd Rudiger Burmester On-site & virtual display
Poster Number: POS0678
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)
Clinical outcomes up to Week (W) 48 in the ongoing filgotinib (FIL) long-term extension (LTE) trial of rheumatoid arthritis (RA) patients (pts) with inadequate response (IR) to methotrexate (MTX) initially treated with FIL or adalimumab (ADA) during the Phase 3 parent study (PS) Bernard Combe, Yoshiya Tanaka, Paul Emery, Alena Pechonkina, Albert Kuo, Qi Gong, Katrien Van Beneden, Vijay Rajendran, Hendrik Schulze-Koops On-site & virtual display
Poster Number: POS0679
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)

Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System Cécile Gaujoux-Viala, Jean-François Bergmann, Mélanie Goguillot, Asma Melaine, Marie Guerin, Alban E On-site & virtual display
Poster Number: POS0627
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)
GLPG4399: selective SIK3 inhibition as a novel mode of action for the treatment of inflammatory arthritic diseases (preclinical) GLPG4399: selective SIK3 inhibition as a novel mode of action for the treatment of inflammatory arthritic diseases (preclinical) On-site & virtual display
Poster Number: POS0442
Date: Wednesday, 1 June 08:00 CEST – Sunday 31 July 2022 23:59 CEST (virtual display; onsite display timings TBC)

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that primarily causes pain, stiffness and swelling in the joints. RA often follows a painful, progressively debilitating course, depriving patients of the ability to continue their daily lives and leading to physical disability. Despite current treatments, RA continues to pose a substantial burden to people living with the disease, comprised of the daily health issues directly related to their RA, such as pain, and the complications of managing comorbid conditions.1,2,3

About the FINCH 4 LTE study
FINCH 4 is an ongoing phase 3 open-label LTE study of filgotinib 200mg and filgotinib 100mg for rheumatoid arthritis (RA) to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in RA. Eligible patients completed a prior phase 3 randomised double-blind study of filgotinib lasting 52 weeks (FINCH 1 or 3) or 24 weeks (FINCH 2).

About filgotinib
Filgotinib is approved and marketed as Jyseleca (200mg and 100mg tablets) in the European Union, Great Britain, and Japan for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). Filgotinib is also approved and marketed as Jyseleca (200mg tablets) in the European Union, Great Britain and Japan for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu. The Great Britain Summary of Product Characteristics for filgotinib can be found at www.medicines.org.uk/emc and the Northern Ireland Summary of Product Characteristics for filgotinib can be found at www.emcmedicines.com/en-GB/northernireland, respectively. The interview form from the Japanese Ministry of Health, Labour and Welfare is available at www.info.pmda.go.jp. A global Phase 3 program with filgotinib is ongoing in Crohn’s Disease. More information about clinical trials can be accessed at https://www.clinicaltrials.gov.

Jyseleca® is a trademark of Galapagos NV and Gilead Sciences, Inc. or its related companies.

About the filgotinib collaboration
Gilead and Galapagos NV are collaborative partners in the global development and commercialization of filgotinib. Galapagos is responsible for the commercialization of filgotinib in Europe, while Gilead remains responsible for filgotinib outside of Europe, including in Japan, where filgotinib is co-marketed with Eisai.

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.

Contact
Investors:
Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:
Marieke Vermeersch
Head of Corporate Communication
+32 479 490 603

media@glpg.com

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with filgotinib may not be completed in the currently envisaged timelines or at all, the inherent risks associated with clinical trial and product development activities, including the filgotinib clinical program and the FINCH 4 LTE study, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), the risks that regulatory authorities will require additional studies, Galapagos' reliance on collaborations with third parties (including our collaboration partner for filgotinib, Gilead) and that Galapagos’ estimations regarding its filgotinib development program and regarding the commercial potential of filgotinib, may be incorrect, the risk that Galapagos will not be able to continue to execute on its currently contemplated business plan and/or will need to revise its business plan, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2021 and our subsequent filings with the U.S. Securities and Exchange Commission (SEC). All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update any forward-looking statements in this document, unless specifically required by law or regulation.


1 Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatology International. 2016;36(5):685-95.
2 Radner H, et al. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis Rheumatology 2011 Feb;50(2):381-8.
3 An J, et al. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis Clin Rheumatol. 2019; 38(10):2717-2726.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye